Reprogramming the Tumor Microenvironment to Improve the Efficacy of Cancer Immunotherapies

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2022 Sep 29

PMID 36175691

Authors

Jabar A Faraj

Ali Jihad Hemid Al-Athari

Sharaf El Din Mohie

Iman Kareem Kadhim

Noor Muhsen Jawad

Weaam J Abbas

Abduladheem Turki Jalil

Affiliations

Soon will be listed here.

Abstract

The immunotherapeutic approaches based on checkpoint inhibitors, tumor vaccination, immune cell-based therapy, and cytokines were developed to engage the patient's immune system against cancer and better survival of them. While potent, however, preclinical and clinical data have identified that abnormalities in the tumor microenvironment (TME) can affect the efficacy of immunotherapies in some cancers. It is therefore imperative to develop new therapeutic interventions that will enable to overcome tumor-supportive TME and restrain anti-tumor immunity in patients that acquire resistance to current immunotherapies. Therefore, recognition of the essential nature of the tolerogenic TME may lead to a shift from the immune-suppressive TME to an immune-stimulating phenotype. Here, we review the composition of the TME and its effect on tumor immunoediting and then present how targeted monotherapy or combination therapies can be employed for reprogramming educated TME to improve current immunotherapies outcomes or elucidate potential therapeutic targets.

Citing Articles

Recent clinical researches and technological development in TIL therapy.

Matsueda S, Chen L, Li H, Yao H, Yu F Cancer Immunol Immunother. 2024; 73(11):232.

PMID: 39264449 PMC: 11393248. DOI: 10.1007/s00262-024-03793-4.

Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?.

Zhao R, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zheng Y Cell Commun Signal. 2024; 22(1):379.

PMID: 39068453 PMC: 11282696. DOI: 10.1186/s12964-024-01743-2.

Multicellular Tumoroids for Investigating Cancer Stem-Like Cells in the Heterogeneous Tumor Microenvironment.

Burkhard K, Mehta G Methods Mol Biol. 2024; 2777:99-122.

PMID: 38478339 DOI: 10.1007/978-1-0716-3730-2_8.

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy.

Mamun M, Zhang Y, Zhao J, Shen D, Guo T, Zheng Y J Biomed Sci. 2023; 30(1):60.

PMID: 37525190 PMC: 10391765. DOI: 10.1186/s12929-023-00952-0.

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

Wang M, Zhu L, Yang X, Li J, Liu Y, Tang Y Front Pharmacol. 2023; 14:1132158.

PMID: 36874015 PMC: 9974851. DOI: 10.3389/fphar.2023.1132158.

References

Yu Y . Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Front Med. 2017; 12(2):229-235. DOI: 10.1007/s11684-017-0581-0. View

Mirsoian A, Bouchlaka M, Sckisel G, Chen M, Pai C, Maverakis E . Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med. 2014; 211(12):2373-83. PMC: 4235633. DOI: 10.1084/jem.20140116. View

Stephan S, Taber A, Jileaeva I, Pegues E, Sentman C, Stephan M . Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014; 33(1):97-101. PMC: 4289408. DOI: 10.1038/nbt.3104. View

Tan S, Li D, Zhu X . Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020; 124:109821. DOI: 10.1016/j.biopha.2020.109821. View

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim E . Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015; 21(5):524-9. PMC: 4425589. DOI: 10.1038/nm.3833. View

Sockolosky J, Trotta E, Parisi G, Picton L, Su L, Le A . Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018; 359(6379):1037-1042. PMC: 5947856. DOI: 10.1126/science.aar3246. View

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y . Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5):761-773. PMC: 5381164. DOI: 10.7150/jca.17648. View

Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D . Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A. 2010; 107(26):11918-23. PMC: 2900704. DOI: 10.1073/pnas.1001749107. View

Headley M, Bins A, Nip A, Roberts E, Looney M, Gerard A . Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature. 2016; 531(7595):513-7. PMC: 4892380. DOI: 10.1038/nature16985. View

10.

Bosi A, Zanellato S, Bassani B, Albini A, Musco A, Cattoni M . Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization. J Immunol Res. 2018; 2018:2438598. PMC: 5896269. DOI: 10.1155/2018/2438598. View

11.

Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L . Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017; 36(31):4457-4468. PMC: 5507301. DOI: 10.1038/onc.2017.65. View

12.

Wang T, Zhao Y, Peng L, Chen N, Chen W, Lv Y . Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017; 66(11):1900-1911. PMC: 5739867. DOI: 10.1136/gutjnl-2016-313075. View

13.

Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld R . Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 2009; 4(11):e7965. PMC: 2775953. DOI: 10.1371/journal.pone.0007965. View

14.

Cheng J, Deng Y, Yi H, Wang G, Fu B, Chen W . Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016; 5:e198. PMC: 5154347. DOI: 10.1038/oncsis.2016.7. View

15.

Elyada E, Bolisetty M, Laise P, Flynn W, Courtois E, Burkhart R . Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019; 9(8):1102-1123. PMC: 6727976. DOI: 10.1158/2159-8290.CD-19-0094. View

16.

Gorchs L, Moro C, Bankhead P, Kern K, Sadeak I, Meng Q . Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4 and CD8 T-Cells. Front Immunol. 2019; 10:847. PMC: 6491453. DOI: 10.3389/fimmu.2019.00847. View

17.

Torres S, Bartolome R, Mendes M, Barderas R, Fernandez-Acenero M, Pelaez-Garcia A . Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res. 2013; 19(21):6006-19. DOI: 10.1158/1078-0432.CCR-13-1130. View

18.

Sakemura R, Hefazi M, Siegler E, Cox M, Larson D, Hansen M . Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022; 139(26):3708-3721. PMC: 11290597. DOI: 10.1182/blood.2021012811. View

19.

Sherman M, Yu R, Engle D, Ding N, Atkins A, Tiriac H . Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014; 159(1):80-93. PMC: 4177038. DOI: 10.1016/j.cell.2014.08.007. View

20.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View